We transform promising life science ideas into medical breakthroughs that change patients’ lives.
Making life science life changing: We transform promising life science ideas into medical breakthroughs that change patients’ lives.
We specialise in early-stage translation – advancing lab-based scientific discoveries to a point at which they can be developed into the next generation of diagnostics, treatments and cures.
Medherant is developing a pipeline of products for pain and neurology indications, based on our next-generation TEPI-Patch® transdermal drug technology. Our first product – Ibuprofen TEPI Patch – entered the clinic in 2018.
Key advantages of the TEPI Patch® technology over current technologies are the high payload and very efficient release of drug. This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch whilst also minimising the residual drug after use.
The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove. No organic solvents are involved in this drug-in-adhesive system.
As well as developing our own products, Medherant offers pharma companies rapid feasibility studies using our proprietary high throughput permeation study system to develop transdermal formulations of their drugs of interest.
Mironid is an innovative drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signaling proteins.
At Nanovery, their cutting-edge DNA nanorobots are revolutionising the biotechnology landscape. As pioneers in nucleic acid nanorobotics (NANs), our platform is the first to provide comprehensive solutions for RNA therapeutic analysis and biomarker quantification. This innovation elevates research precision and simplifies testing protocols.
Their mission is to make the testing processes as simple as possible to drive advancements in biotech research. Nanovery's NANs technology is not just part of biotechnology's future; it is actively shaping it, ensuring their partners stay at the forefront of innovation.
Our vision is to employ new dual-acting retinoic acid receptor modulators (RAR-M) as the basis for developing a new rational effective treatment approach for ALS and meet that unmet need. In the longer term, we see a great opportunity to use our IP from the ALS arena to move on to target the wider range of neurodegenerative diseases.
The NIHR (National Institute for Health Research) funds, enables and delivers world-class health and care research that transforms people’s lives, advances science globally and benefits the UK economy.
The NIHR:
- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy
Oncimmune, a global leader in immunodiagnostics and (auto) antibody biomarker profiling & discovery in immuno-oncology, autoimmune and infectious diseases. Through its ImmunoINSIGHTS™ technology platform, the company provides insights to discover and validate novel biomarkers, improve treatment responses and adverse event (irAE) prediction, patient screening and diagnostic accuracy. Oncimmune is headquartered in the UK with operations in Germany and USA.
